Doy Gay, MD
Family Medicine · Winder, GANPI 1063510782
Payments from drug & device makers
Across 205 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$466
- Otsuka America Pharmaceutical, Inc.$223
- Abbott$180
- Pfizer$165
- Lilly USA, LLC$120
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,517100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,070 |
| GSK | 27 | $466 |
| Otsuka America Pharmaceutical, Inc. | 11 | $223 |
| Abbott | 9 | $180 |
| Pfizer | 13 | $165 |
| Lilly USA, LLC | 7 | $120 |
| Novo Nordisk | 7 | $117 |
| Exact Sciences | 6 | $112 |
| Kowa Pharmaceuticals America, Inc. | 8 | $110 |
| Astellas Pharma US Inc | 6 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $104 |
| Bayer | 5 | $89 |
| Amgen(2 entities) | 5 | $87 |
| Boehringer Ingelheim | 4 | $85 |
| Dexcom, Inc. | 3 | $67 |
| AbbVie | 4 | $61 |
| Novartis | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| Boston Scientific | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Almatica Pharma LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Biomerieux Inc | 1 | $17 |
| Merck | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$121
How this compares
$3,523 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 207 | $183,688 |
| EliquisApixaban | 129 | $131,576 |
| JardianceEmpagliflozin | 111 | $105,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $98,380 |
| OzempicSemaglutide | 30 | $31,587 |
| XareltoRivaroxaban | 31 | $30,090 |
| TrulicityDulaglutide | 22 | $28,914 |
| MounjaroTirzepatide | 25 | $26,941 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $19,580 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,519 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 479 | $10,376 |
| MyrbetriqMirabegron | 13 | $10,101 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $9,421 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $8,538 |
| Potassium Chloride | 247 | $6,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,070 | $183,688207 claims |
| PfizerEliquis | $165 | $131,576129 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $466 | $120,320145 claims |
| Boehringer IngelheimJardiance | $85 | $105,116111 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $120 | $55,85647 claims |
| Novo NordiskOzempic | $117 | $31,58730 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $10,10113 claims |
| AbbVieSynthroid | $61 | $3,46434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Winder
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.